Skip to content
The Prostate Cancer Research Institute (PCRI) recently published the particulars for four clinical trials (Phases 2 and 3) for men with metastatic, castrate-resistant (i.e. PSA progressing with reduced testosterone) prostate cancer. The first Phase 2 trial involves treatment with Enzalutamide (Xtandi or MDV 3100) administered with or without Prostvac. For a brief summary of these therapeutic agents and how they work, see the January 3rd, 2012 website blog. The second is a trial involving the co-administration of Indoximod and Provenge (Sipuleucel). Indoximod is an agent that targets mechanisms by which tumors evade the immune system. The third trial (termed PROMOTE) is studying the gene expression patterns of castrate-resistant patients currently receiving treatment with Zytiga (abiraterone acetate). The fourth is a Phase 3 trial of Prostvac with or without GM-CSF (granulocyte macrophage colony stimulating factor), a protein that functions as a white blood cell growth factor. For additional information, see the links in this blog. For overall clinical trials information, see (1) http://www.clinicaltrials.gov and specifically search for prostate cancer trials; (2) http://www.cancer.gov, a site from the National Cancer Institute, National Institutes of Health; or, (3) for trials being conducted solely in the state of Florida, see http://www.Flcancer.com.